Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163

[1]  F. Tacke,et al.  Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression , 2023, Hepatology.

[2]  F. Avolio,et al.  Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity , 2022, JHEP reports : innovation in hepatology.

[3]  P. Casciato,et al.  The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects , 2022, PloS one.

[4]  S. Moestrup,et al.  Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness , 2022, Hepatology.

[5]  M. Krawczyk,et al.  Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. , 2022, Journal of hepatology.

[6]  S. Spiegel,et al.  A new preclinical model of western diet‐induced progression of non‐alcoholic steatohepatitis to hepatocellular carcinoma , 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  H. Grønbæk,et al.  Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center , 2022, Journal of clinical medicine.

[8]  A. Feuchtinger,et al.  Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication. , 2021, Cell metabolism.

[9]  A. Hanley,et al.  The association of soluble CD163, a novel biomarker of macrophage activation, with type 2 diabetes mellitus and its underlying physiological disorders: A systematic review , 2021, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[10]  A. Adimora,et al.  Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women , 2021, AIDS.

[11]  T. Karlsen,et al.  Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis , 2021, Clinical and translational gastroenterology.

[12]  S. Klein,et al.  Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH , 2021, Cell reports.

[13]  H. Ragab,et al.  Performance of serum CD163 as a marker of fibrosis in patients with NAFLD. , 2020, Diabetes & metabolic syndrome.

[14]  Y. Rotman,et al.  Immunological mechanisms and therapeutic targets of fatty liver diseases , 2020, Cellular & molecular immunology.

[15]  Y. Saeys,et al.  Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver , 2020, Immunity.

[16]  S. Moestrup,et al.  Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases , 2020, International journal of molecular sciences.

[17]  H. Møller,et al.  Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute‐on‐chronic liver failure and acute decompensation , 2020, Journal of gastroenterology and hepatology.

[18]  H. Møller,et al.  Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure , 2020, Cells.

[19]  H. El‐Serag,et al.  Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  C. Glass,et al.  Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. , 2020, Immunity.

[21]  H. Møller,et al.  Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[22]  K. Natarajan,et al.  Transcriptional Dynamics of Hepatic Sinusoid‐Associated Cells After Liver Injury , 2020, Hepatology.

[23]  B. Blagoev,et al.  Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis , 2020, Scientific Reports.

[24]  H. Malhi,et al.  Pathogenesis of Nonalcoholic Steatohepatitis: An Overview , 2020, Hepatology communications.

[25]  R. Weiskirchen,et al.  Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases , 2019, Front. Immunol..

[26]  Jiandie D. Lin,et al.  Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis. , 2019, Molecular cell.

[27]  J. Jelsing,et al.  Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[28]  H. Møller,et al.  Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease , 2018, Journal of pediatric gastroenterology and nutrition.

[29]  Tanveer S. Batth,et al.  Protein Aggregation Capture on Microparticles Enables Multipurpose Proteomics Sample Preparation , 2018, Molecular & Cellular Proteomics.

[30]  D. Schuppan,et al.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Nature Reviews Gastroenterology & Hepatology.

[31]  Ludovic C. Gillet,et al.  Data‐independent acquisition‐based SWATH‐MS for quantitative proteomics: a tutorial , 2018, Molecular systems biology.

[32]  H. Møller,et al.  Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology , 2018, Scandinavian journal of gastroenterology.

[33]  S. Sarin,et al.  Iron-Overload triggers ADAM-17 mediated inflammation in Severe Alcoholic Hepatitis , 2018, Scientific Reports.

[34]  S. Hamilton-Dutoit,et al.  Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment , 2018, Journal of gastroenterology and hepatology.

[35]  B. A. David,et al.  Differential Location and Distribution of Hepatic Immune Cells , 2017, Cells.

[36]  A. Geerts,et al.  Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. , 2017, Cellular immunology.

[37]  A. Bauman,et al.  Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease , 2017, Scandinavian journal of clinical and laboratory investigation.

[38]  A. Kaykas,et al.  ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157 , 2017, Neuroscience Letters.

[39]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[40]  S. Moestrup,et al.  Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes , 2016, Molecular therapy. Methods & clinical development.

[41]  B. Bibby,et al.  The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[42]  H. Møller,et al.  Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma , 2016, Scandinavian journal of clinical and laboratory investigation.

[43]  R. Chung,et al.  Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease , 2015, Clinical and Translational Gastroenterology.

[44]  K. Clément,et al.  Macrophage activation marker soluble CD163 and non‐alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery , 2015, Journal of gastroenterology and hepatology.

[45]  H. Møller,et al.  The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children , 2015, Pediatric obesity.

[46]  S. Horgan,et al.  Benefits of bariatric surgery do not reach obese men. , 2014, Journal of laparoendoscopic & advanced surgical techniques. Part A.

[47]  S. Hamilton-Dutoit,et al.  Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study , 2014, The American Journal of Gastroenterology.

[48]  B. Bibby,et al.  Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C , 2014, Hepatology.

[49]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[50]  H. Randeva,et al.  Elevated Soluble CD163 in Gestational Diabetes Mellitus: Secretion from Human Placenta and Adipose Tissue , 2014, PloS one.

[51]  Z. Kováčová,et al.  Soluble CD163 is associated with CD163 mRNA expression in adipose tissue and with insulin sensitivity in steady-state condition but not in response to calorie restriction. , 2014, The Journal of clinical endocrinology and metabolism.

[52]  S. Terai,et al.  Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans , 2013, PloS one.

[53]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[54]  G. Ioannou,et al.  Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis[S] , 2013, Journal of Lipid Research.

[55]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[56]  T. Burdo,et al.  Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal‐weight subjects , 2012, Clinical endocrinology.

[57]  B. Bibby,et al.  Soluble CD163: a biomarker linking macrophages and insulin resistance , 2012, Diabetologia.

[58]  H. Møller.  Soluble CD163 , 2012, Scandinavian journal of clinical and laboratory investigation.

[59]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[60]  B. Nordestgaard,et al.  Serum soluble CD163 predicts risk of type 2 diabetes in the general population. , 2011, Clinical chemistry.

[61]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[62]  S. Moestrup,et al.  Characterization of an enzyme-linked immunosorbent assay for soluble CD163 , 2002, Scandinavian journal of clinical and laboratory investigation.

[63]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[64]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[65]  S. Moestrup,et al.  Tumor necrosis factor -converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163 , 2010 .

[66]  R. Engle,et al.  Corresponding author. , 2004 .